Selenium in the Treatment of Head and Neck Lymphedema
Objective: To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery. Subjects and Materials: Between June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were tre...
Saved in:
Published in | Medical principles and practice Vol. 13; no. 4; pp. 185 - 190 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Basel, Switzerland
01.01.2004
|
Subjects | |
Online Access | Get full text |
ISSN | 1011-7571 1423-0151 1423-0151 |
DOI | 10.1159/000078313 |
Cover
Abstract | Objective: To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery. Subjects and Materials: Between June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were treated with selenium for persistent, extensive or progressive lymphedema of the head and neck region. Twenty had interstitial endolaryngeal edema associated with stridor and dyspnea. All patients received 350 µg/m 2 body surface sodium selenite medication p.o. daily (total dose 50 µg per day) for a period of 4–6 weeks after radiotherapy. The optimal effect of the selenium treatment was assessed after 4 weeks of therapy using the Miller score system. A visual analogue scale on a scale of 0–10 was used to assess the patient’s quality of life prior to and after selenium. Results: 75% of the patients had an improvement of the Miller score of one stage or more. The self-assessment of quality of life using the visual analogue scale improved significantly after selenium treatment with a reduction of 4.4 points (p < 0.05). Of the 20 patients with endolaryngeal edema tracheostomy was not necessary in 13 patients (65%), but 5 and 2 received a temporary or permanent tracheostomy, respectively. No episode of erysipelas was observed in all study patients. Conclusion: Our results suggest a short positive effect of sodium selenite on secondary head and neck lymphedema caused by radiotherapy alone or in combination with surgery. |
---|---|
AbstractList | To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery.
Between June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were treated with selenium for persistent, extensive or progressive lymphedema of the head and neck region. Twenty had interstitial endolaryngeal edema associated with stridor and dyspnea. All patients received 350 microg/m(2) body surface sodium selenite medication p.o. daily (total dose 50 microg per day) for a period of 4-6 weeks after radiotherapy. The optimal effect of the selenium treatment was assessed after 4 weeks of therapy using the Miller score system. A visual analogue scale on a scale of 0-10 was used to assess the patient's quality of life prior to and after selenium.
75% of the patients had an improvement of the Miller score of one stage or more. The self-assessment of quality of life using the visual analogue scale improved significantly after selenium treatment with a reduction of 4.4 points (p < 0.05). Of the 20 patients with endolaryngeal edema tracheostomy was not necessary in 13 patients (65%), but 5 and 2 received a temporary or permanent tracheostomy, respectively. No episode of erysipelas was observed in all study patients.
Our results suggest a short positive effect of sodium selenite on secondary head and neck lymphedema caused by radiotherapy alone or in combination with surgery. Objective: To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery. Subjects and Materials: Between June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were treated with selenium for persistent, extensive or progressive lymphedema of the head and neck region. Twenty had interstitial endolaryngeal edema associated with stridor and dyspnea. All patients received 350 µg/m 2 body surface sodium selenite medication p.o. daily (total dose 50 µg per day) for a period of 4–6 weeks after radiotherapy. The optimal effect of the selenium treatment was assessed after 4 weeks of therapy using the Miller score system. A visual analogue scale on a scale of 0–10 was used to assess the patient’s quality of life prior to and after selenium. Results: 75% of the patients had an improvement of the Miller score of one stage or more. The self-assessment of quality of life using the visual analogue scale improved significantly after selenium treatment with a reduction of 4.4 points (p < 0.05). Of the 20 patients with endolaryngeal edema tracheostomy was not necessary in 13 patients (65%), but 5 and 2 received a temporary or permanent tracheostomy, respectively. No episode of erysipelas was observed in all study patients. Conclusion: Our results suggest a short positive effect of sodium selenite on secondary head and neck lymphedema caused by radiotherapy alone or in combination with surgery. To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery.OBJECTIVETo investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery.Between June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were treated with selenium for persistent, extensive or progressive lymphedema of the head and neck region. Twenty had interstitial endolaryngeal edema associated with stridor and dyspnea. All patients received 350 microg/m(2) body surface sodium selenite medication p.o. daily (total dose 50 microg per day) for a period of 4-6 weeks after radiotherapy. The optimal effect of the selenium treatment was assessed after 4 weeks of therapy using the Miller score system. A visual analogue scale on a scale of 0-10 was used to assess the patient's quality of life prior to and after selenium.SUBJECTS AND MATERIALSBetween June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were treated with selenium for persistent, extensive or progressive lymphedema of the head and neck region. Twenty had interstitial endolaryngeal edema associated with stridor and dyspnea. All patients received 350 microg/m(2) body surface sodium selenite medication p.o. daily (total dose 50 microg per day) for a period of 4-6 weeks after radiotherapy. The optimal effect of the selenium treatment was assessed after 4 weeks of therapy using the Miller score system. A visual analogue scale on a scale of 0-10 was used to assess the patient's quality of life prior to and after selenium.75% of the patients had an improvement of the Miller score of one stage or more. The self-assessment of quality of life using the visual analogue scale improved significantly after selenium treatment with a reduction of 4.4 points (p < 0.05). Of the 20 patients with endolaryngeal edema tracheostomy was not necessary in 13 patients (65%), but 5 and 2 received a temporary or permanent tracheostomy, respectively. No episode of erysipelas was observed in all study patients.RESULTS75% of the patients had an improvement of the Miller score of one stage or more. The self-assessment of quality of life using the visual analogue scale improved significantly after selenium treatment with a reduction of 4.4 points (p < 0.05). Of the 20 patients with endolaryngeal edema tracheostomy was not necessary in 13 patients (65%), but 5 and 2 received a temporary or permanent tracheostomy, respectively. No episode of erysipelas was observed in all study patients.Our results suggest a short positive effect of sodium selenite on secondary head and neck lymphedema caused by radiotherapy alone or in combination with surgery.CONCLUSIONOur results suggest a short positive effect of sodium selenite on secondary head and neck lymphedema caused by radiotherapy alone or in combination with surgery. Objective: To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery. Subjects and Materials: Between June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were treated with selenium for persistent, extensive or progressive lymphedema of the head and neck region. Twenty had interstitial endolaryngeal edema associated with stridor and dyspnea. All patients received 350 µg/m2 body surface sodium selenite medication p.o. daily (total dose 50 µg per day) for a period of 4–6 weeks after radiotherapy. The optimal effect of the selenium treatment was assessed after 4 weeks of therapy using the Miller score system. A visual analogue scale on a scale of 0–10 was used to assess the patient’s quality of life prior to and after selenium. Results: 75% of the patients had an improvement of the Miller score of one stage or more. The self-assessment of quality of life using the visual analogue scale improved significantly after selenium treatment with a reduction of 4.4 points (p < 0.05). Of the 20 patients with endolaryngeal edema tracheostomy was not necessary in 13 patients (65%), but 5 and 2 received a temporary or permanent tracheostomy, respectively. No episode of erysipelas was observed in all study patients. Conclusion: Our results suggest a short positive effect of sodium selenite on secondary head and neck lymphedema caused by radiotherapy alone or in combination with surgery. |
Author | Büntzel, J. Micke, O. Kisters, K. Schönekaes, K. Mücke, R. Bruns, F. |
Author_xml | – sequence: 1 givenname: F. surname: Bruns fullname: Bruns, F. – sequence: 2 givenname: J. surname: Büntzel fullname: Büntzel, J. – sequence: 3 givenname: R. surname: Mücke fullname: Mücke, R. – sequence: 4 givenname: K. surname: Schönekaes fullname: Schönekaes, K. – sequence: 5 givenname: K. surname: Kisters fullname: Kisters, K. – sequence: 6 givenname: O. surname: Micke fullname: Micke, O. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15181321$$D View this record in MEDLINE/PubMed |
BookMark | eNp90N9LwzAQB_AgE_dDH3wWpPggKNTleu3WPMpQJ0wdOJ9Lml5dXZvWtEX239vZMUGGeUkgn_teLn3W0bkmxk6B3wB4YsibNfYR8ID1wHXQ5uBBpzlzAHvsjaHL-mX50SgfkR-xbnPtAzrQY94rpaSTOrMSbVVLshaGZJWRrqw8tqYkI0vqyHomtbJm66xYUkSZPGaHsUxLOtnuA_Z2f7eYTO3Zy8Pj5HZmKxxhZTsYqpB7gmOMRD5GkeLhyOeIftw8jfsOkRi5ygPlhEQjBJcUCfJBuUrEDg7YdZtb60Kuv2SaBoVJMmnWAfBgM3uwm73Bly0uTP5ZU1kFWVIqSlOpKa_LYAxCCBSb1PMtrMOMot_I7a804KoFyuRlaSj-t-vwj1VJJask15WRSbq34qKtWEnzTmaX_TSf_4CgiOIGne1FbcQ3fXqR5w |
CitedBy_id | crossref_primary_10_1016_j_oraloncology_2015_01_005 crossref_primary_10_1093_jncimonographs_lgz005 crossref_primary_10_1111_ecc_12894 crossref_primary_10_1055_a_1746_1932 crossref_primary_10_12968_bjcn_2021_26_Sup4_S24 crossref_primary_10_1089_ars_2010_3275 crossref_primary_10_3390_nu11051021 crossref_primary_10_1089_lrb_2004_2_183 crossref_primary_10_1016_j_ijrobp_2012_04_013 crossref_primary_10_1097_MD_0000000000030910 crossref_primary_10_1017_S1446545000000026 crossref_primary_10_1089_jpm_2016_0174 crossref_primary_10_1055_a_1558_5820 crossref_primary_10_1089_lrb_2004_2_147 crossref_primary_10_1007_s00129_007_2056_x crossref_primary_10_1590_0103_5150_029_002_AO20 crossref_primary_10_1001_jamaoto_2023_1473 crossref_primary_10_1002_hed_27136 crossref_primary_10_1016_j_hoc_2008_04_012 crossref_primary_10_1055_s_0042_1745726 crossref_primary_10_3390_nu13093253 crossref_primary_10_1055_a_1263_2976 crossref_primary_10_1188_11_ONF_E1_E10 crossref_primary_10_3109_13880209_2012_749923 crossref_primary_10_1080_09638288_2024_2366004 crossref_primary_10_1371_journal_pone_0026259 crossref_primary_10_1007_s11764_023_01453_7 crossref_primary_10_1007_s00761_007_1199_7 crossref_primary_10_1089_ars_2009_2884 crossref_primary_10_1007_s40268_021_00340_9 crossref_primary_10_1055_a_1545_2202 crossref_primary_10_1002_hed_23084 crossref_primary_10_1016_j_bjps_2006_04_013 crossref_primary_10_1016_j_amjoto_2019_05_024 crossref_primary_10_1055_a_1837_4511 crossref_primary_10_1089_lrb_2017_0074 crossref_primary_10_1007_s00520_011_1294_6 crossref_primary_10_1007_s00761_013_2461_9 crossref_primary_10_1007_s13126_020_0548_5 crossref_primary_10_1188_13_ONF_501_506 crossref_primary_10_3390_molecules14103975 crossref_primary_10_1002_hed_21001 crossref_primary_10_1007_s15013_016_1000_3 crossref_primary_10_3892_mco_2018_1663 |
Cites_doi | 10.1007/s001060050303 10.1016/S0140-6736(00)02490-9 10.1002/(SICI)1097-0142(19981215)83:12B+<2886::AID-CNCR46>3.0.CO;2-M 10.1016/0360-3016(95)00057-6 10.1016/S0002-9343(00)00727-0 10.1002/(SICI)1097-0142(19981215)83:12B+<2882::AID-CNCR45>3.0.CO;2-0 10.1385/BTER:73:2:97 10.1046/j.1524-4741.2000.99072.x 10.1002/(SICI)1097-0142(19981215)83:12B+<2833::AID-CNCR35>3.0.CO;2-3 10.1056/NEJM199310143291604 10.1097/00002060-200110000-00001 10.1042/CS20000299 |
ContentType | Journal Article |
Copyright | 2004 S. Karger AG, Basel Copyright 2004 S. Karger AG, Basel |
Copyright_xml | – notice: 2004 S. Karger AG, Basel – notice: Copyright 2004 S. Karger AG, Basel |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTOC UNPAY |
DOI | 10.1159/000078313 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1423-0151 |
EndPage | 190 |
ExternalDocumentID | 10.1159/000078313 15181321 10_1159_000078313 78313 |
Genre | Clinical Trial Journal Article |
GroupedDBID | --- 0R~ 0~B 30W 326 36B 3O. 3V. 4.4 53G 5GY 7X7 88E 8FI 8FJ 8UI AAWTL AAYIC ABPAZ ABUWG ACGFS ADAGL ADBBV AENEX AEYAO AFJJK AFKRA AHMBA AIOBO ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZPMC BAWUL BCNDV BENPR BPHCQ BVXVI CAG CCPQU COF CS3 CYUIP DIK DU5 E0A E3Z EBS EJD EMB EMOBN F5P FB. FYUFA GROUPED_DOAJ HMCUK HYE HZ~ IAO IHR KUZGX M-- M1P MK0 O1H O9- OK1 P2P PQQKQ PROAC PSQYO RIG RKO RNS RPM RXVBD SV3 TR2 UJ6 UKHRP AAYXX ABBTS ABWCG ACQXL AFSIO AHFRZ CITATION ITC PHGZM PHGZT PJZUB PPXIY PUEGO CGR CUY CVF ECM EIF NPM 7X8 ADTOC UNPAY |
ID | FETCH-LOGICAL-c363t-23bcb05903f3ee83ddc0b680338f011082ee964c51c2bee6314ece9e81c4c9f23 |
IEDL.DBID | UNPAY |
ISSN | 1011-7571 1423-0151 |
IngestDate | Tue Aug 19 21:33:30 EDT 2025 Thu Sep 04 15:42:16 EDT 2025 Wed Feb 19 01:41:39 EST 2025 Wed Oct 01 06:30:46 EDT 2025 Thu Apr 24 23:05:01 EDT 2025 Thu Aug 29 12:04:28 EDT 2024 Thu Sep 05 17:58:24 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Glutathione peroxidase Sodium selenite Lymphedema Head and neck cancer Selenium Radiotherapy Endolaryngeal edema |
Language | English |
License | Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. https://www.karger.com/Services/SiteLicenses Copyright 2004 S. Karger AG, Basel |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c363t-23bcb05903f3ee83ddc0b680338f011082ee964c51c2bee6314ece9e81c4c9f23 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://www.karger.com/Article/Pdf/78313 |
PMID | 15181321 |
PQID | 71999392 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_71999392 crossref_citationtrail_10_1159_000078313 pubmed_primary_15181321 karger_primary_78313 unpaywall_primary_10_1159_000078313 crossref_primary_10_1159_000078313 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2004-01-01 |
PublicationDateYYYYMMDD | 2004-01-01 |
PublicationDate_xml | – month: 01 year: 2004 text: 2004-01-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Basel, Switzerland |
PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland |
PublicationTitle | Medical principles and practice |
PublicationTitleAlternate | Med Princ Pract |
PublicationYear | 2004 |
References | Whanger PD: Selenoprotein W: A review. Cell Mol Life Sci 2000;57:1846-1852. Petrek JA, Pressman PI, Smith RA: Lymphedema: Current issues in research and management. CA Cancer J Clin 2000;50:292-307. Miller AJ, Bruna J, Beninson J: A universally applicable clinical classification of lymphedema. Angiology 1999;50:189-192. Rockson SG, Miller LT, Senie R, Brennan MJ, Casley-Smith JR, Földi E, Földi M, Gamble GL, Kasseroller RG, Leduc A, Lerner R, Mortimer PS, Norman SA, Plotkin CL, Rinehart-Ayres ME, Walder AL: American Cancer Society Lymphedema Workshop. Workgroup III: Diagnosis and management of lymphedema. Cancer 1998;83:2882-2885.987441710.1002/(SICI)1097-0142(19981215)83:12B+<2882::AID-CNCR45>3.0.CO;2-0 Földi E: Treatment of lymphedema and patient rehabilitation. Anticancer Res 1998;18:2211-2212. Weissleder H, Schuchardt C: Iatrogenic alteration of the lymphatic system; in Weissleder H, Schuchardt C (eds): Lymphedema: Diagnosis and Therapy, ed 3. Cologne, Viavital, 2001, pp 156-174. Mücke R, Micke O, Schönekaes KG: Serum selenium levels, glutathione peroxidase activities and serum redox potential levels in patients with untreated non-small cell lung cancer and adenocarcinoma of the rectum. Trace Elem Electrolytes 2003;20:148. Peters GM, Herbert WD: Reduction of edema in brain tumors by selenium application. Acta Neurol Pathol Oncol 1957;11:351-353. Piller NB: Macrophage and tissue changes in the developmental phases of secondary lymphoedema and during conservative therapy with benzopyrone. Arch Histol Cytol 1990;53:209-218.2252630 Bruns F, Micke O, Bremer M: Current status of selenium and other treatments for secondary lymphedema. J Support Oncol 2003;1:121-138. Casley-Smith JR: Benzo-pyrones in the treatment of lymphoedema. Int Angiol 1999;18:31-41. Loprinzi CL, Sloan J, Kugler J: Coumarin-induced hepatotoxicity. JCO 1997;15:3167-3168. Beier A, Siems W, Brenke R, Grune T: Increased formation of free radicals in chronic lymphedema. Z Lymphol 1994;18:8-11. Brenke R, Siems W: Adjuvant therapy in lymphedema. Z Lymphol 1996;20:31-35. Casley-Smith JR, Gaffney RM: Excess plasma proteins as a cause of chronic inflammation and lymphodema: Quantitative electron microscopy. J Pathol 1981;133:243-272.7463213 Rockson SG: Lymphedema. Am J Med 2001;110:288-295.1123984710.1016/S0002-9343(00)00727-0 Rubin P, Constine LS, Fajardo LF, Phillips TL, Wasserman TH: RTOG Late Effects Working Group. Overview. Late Effects on Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 1995;31:1041-1042.10.1016/0360-3016(95)00057-6 Kiremidjian-Schumacher L, Roy M, Glickman R, Schneider K, Rothstein S, Cooper J, Hochster H, Kim M, Newman R: Selenium and immunocompetence in patients with head and neck cancer. Biol Trace Elem Res 2000;73:97-111.1104920310.1385/BTER:73:2:97 Rayman MP: The importance of selenium to human health. Lancet 2000;356:233-241.1096321210.1016/S0140-6736(00)02490-9 Johnson EW: Visual analog scale (VAS). Am J Phys Med Rehabil 2001;80:717.10.1097/00002060-200110000-00001 Herpertz U: Measuring and documentation of edema. Z Lymphol 1994;18:24-30. Bahadur S, Amatya RC, Kacker SK: The enigma of post-radiation oedema and residual or recurrent carcinoma of the larynx and pyriform fossa. J Laryngol Otol 1985;99:763-765. Megens A, Harris SR: Physical therapist management of lymphedema following treatment for breast cancer: A critical review of its effectiveness. Phys Ther 1998;78:1302-1311. Ewald H: Radiotherapy of head and neck tumours and risk of lymphedema (in German). Z Lymphol 1996;20:21-26 Casley-Smith JR, Morgan RG, Piller NB: Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. N Engl J Med 1993;329:1158-1163.837777910.1056/NEJM199310143291604 Micke O, Bruns F, Schäfer U, Kisters K, Hesselmann S, Willich N: Selenium in the treatment of acute and chronic lymphedema. Trace Elem Electrolytes 2000;17:206-209. Dietz A, Rudat V, Nollert J, Helbig M, Vanselow B, Weidauer H: Chronic laryngeal edema as a late reaction to radiochemotherapy. HNO 1998;46:731-738.10.1007/s001060050303 Miller S, Walker SW, Arthur JR, Nicol F, Pickard K, Lewin MH, Howie AF, Beckett GJ: Selenite protects human endothelial cells from oxidative damage and induces thioredoxin reductase. Clin Sci (Lond) 2001;100:543-550.1129469510.1042/CS20000299 Földi E: The treatment of lymphedema. Cancer 1998;83:2833-2834.10.1002/(SICI)1097-0142(19981215)83:12B+<2833::AID-CNCR35>3.0.CO;2-3 Kasseroller RG, Schrauzer GN: Treatment of secondary lymphedema of the arm with physical decongestive therapy and sodium selenite: A review. Am J Ther 2000;7:273-279. Obenheimer H, Jankowiak P, Berlemann K, Hermann V, Diethelm A: Clinical and biological effects of selenium in edema; in Gonzalez G (ed): Lymphedema: New Perspectives in Research and Treatment. Zaragossa, 1976. Kasseroller R: Sodium selenite as prophylaxis against erysipelas in secondary lymphedema. Anticancer Res 1998;18:2227-2230. Schuchardt C, Pritschow H, Weissleder H: Conservative treatment; in Weissleder H, Schuchardt C (eds): Lymphedema: Diagnosis and Therapy, ed 3. Cologne, Viavital, 2001, pp 336-358. Paskett ED, Stark N: Lymphedema: Knowledge, Treatment, and Impact among Breast Cancer Survivors. Breast J 2000;6:373-378.10.1046/j.1524-4741.2000.99072.x Walley DR, Augustine E, Saslow D, Bailey S, Jeffs E, Lasinski B, Plotkin J, Walker M: American Cancer Society Lymphedema Workshop. Workgroup IV: Lymphedema treatment resources-professional education and availability of patient services. Cancer 1998;83:2886-2887.10.1002/(SICI)1097-0142(19981215)83:12B+<2886::AID-CNCR46>3.0.CO;2-M Weissleder H, Schuchardt C: Lymphedema of the arm following breast cancer therapy; in Weissleder H, Schuchardt C (eds): Lymphedema: Diagnosis and Therapy, ed 3. Cologne, Viavital, 2001, pp 187-213. Horvathova M, Jahnova E, Gazdik F: Effect of selenium supplementation in asthmatic subjects on the expression of endothelial cell adhesion molecules in culture. Biol Trace Elem Res 1999;69:15-26. Schünemann H, Willich N: Lymphoedema of the arm after treatment of cancer of the breast: A study of 5868 cases. Dtsch Med Wochenschr 1997;122:536-541. ref8 ref7 ref12 ref9 ref4 ref3 ref6 ref11 ref5 ref10 ref2 ref1 |
References_xml | – reference: Schünemann H, Willich N: Lymphoedema of the arm after treatment of cancer of the breast: A study of 5868 cases. Dtsch Med Wochenschr 1997;122:536-541. – reference: Herpertz U: Measuring and documentation of edema. Z Lymphol 1994;18:24-30. – reference: Bruns F, Micke O, Bremer M: Current status of selenium and other treatments for secondary lymphedema. J Support Oncol 2003;1:121-138. – reference: Brenke R, Siems W: Adjuvant therapy in lymphedema. Z Lymphol 1996;20:31-35. – reference: Obenheimer H, Jankowiak P, Berlemann K, Hermann V, Diethelm A: Clinical and biological effects of selenium in edema; in Gonzalez G (ed): Lymphedema: New Perspectives in Research and Treatment. Zaragossa, 1976. – reference: Paskett ED, Stark N: Lymphedema: Knowledge, Treatment, and Impact among Breast Cancer Survivors. Breast J 2000;6:373-378.10.1046/j.1524-4741.2000.99072.x – reference: Piller NB: Macrophage and tissue changes in the developmental phases of secondary lymphoedema and during conservative therapy with benzopyrone. Arch Histol Cytol 1990;53:209-218.2252630 – reference: Rockson SG: Lymphedema. Am J Med 2001;110:288-295.1123984710.1016/S0002-9343(00)00727-0 – reference: Walley DR, Augustine E, Saslow D, Bailey S, Jeffs E, Lasinski B, Plotkin J, Walker M: American Cancer Society Lymphedema Workshop. Workgroup IV: Lymphedema treatment resources-professional education and availability of patient services. Cancer 1998;83:2886-2887.10.1002/(SICI)1097-0142(19981215)83:12B+<2886::AID-CNCR46>3.0.CO;2-M – reference: Bahadur S, Amatya RC, Kacker SK: The enigma of post-radiation oedema and residual or recurrent carcinoma of the larynx and pyriform fossa. J Laryngol Otol 1985;99:763-765. – reference: Whanger PD: Selenoprotein W: A review. Cell Mol Life Sci 2000;57:1846-1852. – reference: Johnson EW: Visual analog scale (VAS). Am J Phys Med Rehabil 2001;80:717.10.1097/00002060-200110000-00001 – reference: Rayman MP: The importance of selenium to human health. Lancet 2000;356:233-241.1096321210.1016/S0140-6736(00)02490-9 – reference: Kasseroller RG, Schrauzer GN: Treatment of secondary lymphedema of the arm with physical decongestive therapy and sodium selenite: A review. Am J Ther 2000;7:273-279. – reference: Beier A, Siems W, Brenke R, Grune T: Increased formation of free radicals in chronic lymphedema. Z Lymphol 1994;18:8-11. – reference: Horvathova M, Jahnova E, Gazdik F: Effect of selenium supplementation in asthmatic subjects on the expression of endothelial cell adhesion molecules in culture. Biol Trace Elem Res 1999;69:15-26. – reference: Rockson SG, Miller LT, Senie R, Brennan MJ, Casley-Smith JR, Földi E, Földi M, Gamble GL, Kasseroller RG, Leduc A, Lerner R, Mortimer PS, Norman SA, Plotkin CL, Rinehart-Ayres ME, Walder AL: American Cancer Society Lymphedema Workshop. Workgroup III: Diagnosis and management of lymphedema. Cancer 1998;83:2882-2885.987441710.1002/(SICI)1097-0142(19981215)83:12B+<2882::AID-CNCR45>3.0.CO;2-0 – reference: Micke O, Bruns F, Schäfer U, Kisters K, Hesselmann S, Willich N: Selenium in the treatment of acute and chronic lymphedema. Trace Elem Electrolytes 2000;17:206-209. – reference: Weissleder H, Schuchardt C: Iatrogenic alteration of the lymphatic system; in Weissleder H, Schuchardt C (eds): Lymphedema: Diagnosis and Therapy, ed 3. Cologne, Viavital, 2001, pp 156-174. – reference: Megens A, Harris SR: Physical therapist management of lymphedema following treatment for breast cancer: A critical review of its effectiveness. Phys Ther 1998;78:1302-1311. – reference: Petrek JA, Pressman PI, Smith RA: Lymphedema: Current issues in research and management. CA Cancer J Clin 2000;50:292-307. – reference: Kiremidjian-Schumacher L, Roy M, Glickman R, Schneider K, Rothstein S, Cooper J, Hochster H, Kim M, Newman R: Selenium and immunocompetence in patients with head and neck cancer. Biol Trace Elem Res 2000;73:97-111.1104920310.1385/BTER:73:2:97 – reference: Weissleder H, Schuchardt C: Lymphedema of the arm following breast cancer therapy; in Weissleder H, Schuchardt C (eds): Lymphedema: Diagnosis and Therapy, ed 3. Cologne, Viavital, 2001, pp 187-213. – reference: Casley-Smith JR: Benzo-pyrones in the treatment of lymphoedema. Int Angiol 1999;18:31-41. – reference: Rubin P, Constine LS, Fajardo LF, Phillips TL, Wasserman TH: RTOG Late Effects Working Group. Overview. Late Effects on Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 1995;31:1041-1042.10.1016/0360-3016(95)00057-6 – reference: Földi E: Treatment of lymphedema and patient rehabilitation. Anticancer Res 1998;18:2211-2212. – reference: Földi E: The treatment of lymphedema. Cancer 1998;83:2833-2834.10.1002/(SICI)1097-0142(19981215)83:12B+<2833::AID-CNCR35>3.0.CO;2-3 – reference: Ewald H: Radiotherapy of head and neck tumours and risk of lymphedema (in German). Z Lymphol 1996;20:21-26 – reference: Dietz A, Rudat V, Nollert J, Helbig M, Vanselow B, Weidauer H: Chronic laryngeal edema as a late reaction to radiochemotherapy. HNO 1998;46:731-738.10.1007/s001060050303 – reference: Loprinzi CL, Sloan J, Kugler J: Coumarin-induced hepatotoxicity. JCO 1997;15:3167-3168. – reference: Casley-Smith JR, Gaffney RM: Excess plasma proteins as a cause of chronic inflammation and lymphodema: Quantitative electron microscopy. J Pathol 1981;133:243-272.7463213 – reference: Miller AJ, Bruna J, Beninson J: A universally applicable clinical classification of lymphedema. Angiology 1999;50:189-192. – reference: Miller S, Walker SW, Arthur JR, Nicol F, Pickard K, Lewin MH, Howie AF, Beckett GJ: Selenite protects human endothelial cells from oxidative damage and induces thioredoxin reductase. Clin Sci (Lond) 2001;100:543-550.1129469510.1042/CS20000299 – reference: Kasseroller R: Sodium selenite as prophylaxis against erysipelas in secondary lymphedema. Anticancer Res 1998;18:2227-2230. – reference: Schuchardt C, Pritschow H, Weissleder H: Conservative treatment; in Weissleder H, Schuchardt C (eds): Lymphedema: Diagnosis and Therapy, ed 3. Cologne, Viavital, 2001, pp 336-358. – reference: Peters GM, Herbert WD: Reduction of edema in brain tumors by selenium application. Acta Neurol Pathol Oncol 1957;11:351-353. – reference: Mücke R, Micke O, Schönekaes KG: Serum selenium levels, glutathione peroxidase activities and serum redox potential levels in patients with untreated non-small cell lung cancer and adenocarcinoma of the rectum. Trace Elem Electrolytes 2003;20:148. – reference: Casley-Smith JR, Morgan RG, Piller NB: Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. N Engl J Med 1993;329:1158-1163.837777910.1056/NEJM199310143291604 – ident: ref7 doi: 10.1007/s001060050303 – ident: ref10 doi: 10.1016/S0140-6736(00)02490-9 – ident: ref5 doi: 10.1002/(SICI)1097-0142(19981215)83:12B+<2886::AID-CNCR46>3.0.CO;2-M – ident: ref8 doi: 10.1016/0360-3016(95)00057-6 – ident: ref1 doi: 10.1016/S0002-9343(00)00727-0 – ident: ref6 doi: 10.1002/(SICI)1097-0142(19981215)83:12B+<2882::AID-CNCR45>3.0.CO;2-0 – ident: ref12 doi: 10.1385/BTER:73:2:97 – ident: ref2 doi: 10.1046/j.1524-4741.2000.99072.x – ident: ref3 doi: 10.1002/(SICI)1097-0142(19981215)83:12B+<2833::AID-CNCR35>3.0.CO;2-3 – ident: ref4 doi: 10.1056/NEJM199310143291604 – ident: ref9 doi: 10.1097/00002060-200110000-00001 – ident: ref11 doi: 10.1042/CS20000299 |
SSID | ssj0008330 |
Score | 1.8319322 |
Snippet | Objective: To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with... To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery.... To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with... |
SourceID | unpaywall proquest pubmed crossref karger |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 185 |
SubjectTerms | Aged Chemotherapy, Adjuvant Female Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - psychology Head and Neck Neoplasms - radiotherapy Humans Lymphedema - drug therapy Lymphedema - psychology Lymphedema - radiotherapy Male Middle Aged Original Paper Quality of Life Sodium Selenite - therapeutic use |
Title | Selenium in the Treatment of Head and Neck Lymphedema |
URI | https://karger.com/doi/10.1159/000078313 https://www.ncbi.nlm.nih.gov/pubmed/15181321 https://www.proquest.com/docview/71999392 https://www.karger.com/Article/Pdf/78313 |
UnpaywallVersion | publishedVersion |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1423-0151 dateEnd: 20241003 omitProxy: true ssIdentifier: ssj0008330 issn: 1423-0151 databaseCode: DIK dateStart: 19980101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED-hDgF7GB8bLAyGBTzwkjW248R5nKZN5aNVJVZpPEX-uEhTu7SijdD467ETt4NpSHuL7Iuc-Gzd73zn3wF8pKhEUhkeK6plnGrq9pxA9yQ0y5m1Whp_33k4ygaT9MuFuAjnHcuQVjn1OdAtPWr_uJu-_thW_VxyX552K_OhpB5sTUbj4x9tMJPSOBedb-XQgfOOBQ0kQs5Yt_yM7bv_mJ6H3Sh3ActteNzUC3X9S81mfxmbs6cd89Gy5Sj0OSbTo2alj8zvWwyO9_mPZ7ATECcJfc_hAdYv4NEwxNR3QXz3lueyuSKXNXFwkJyvc8_JvCIDtwaIqi0ZoZmSb9dO-WjxSu3B5Oz0_GQQh2IKseEZX8WMa6P9TVNecUTJrTWJzmTiXNTKYwDJEIssNYIaphEzTlM0WKCkJjVFxfhL6NXzGveBSElVwg3LBdOpFKrgSltVGF4lRjn3KoJP63kuTWAa9wUvZmXrcYii3Kgkgvcb0UVHr3GX0G43lRuR0Hxwq3k4Hrc95cJWEbxbK7Z0O8aHQVSN82ZZ5p55wcHCCF51-r4ZWTi8wxmN4MNmAfz_s17fS-oAnnTJPv7U5g30Vj8bfOtwzEofOgT_-ethWMh_AFez7CU |
linkProvider | Unpaywall |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swED9KOvbx0H1069yPVWx72IsbS7Js-bGMljCWEGgD3ZPRxxlKUicsMaX76yfZSraVDvpmpDOydRL3O93pdwCfKSqRVIbHimoZp5q6PSfQPQnNcmatlsbfdx6OssEk_XYlrsJ5xzKkVU59DnRLj9o_7aavP7ZVP5fcl6fdznwoqQfbk9H49EcbzKQ0zkXnWzl04LxjQQOJkDPWLT9j--4_pudJN8pDwPIFPGvqhbq7VbPZX8bm_GXHfLRsOQp9jsn0pFnpE_PrHoPjY_7jFewExElC32vYwvoNPB2GmPouiAtvea6bG3JdEwcHyeU695zMKzJwa4Co2pIRmin5fueUjxZv1FuYnJ9dfh3EoZhCbHjGVzHj2mh_05RXHFFya02iM5k4F7XyGEAyxCJLjaCGacSM0xQNFiipSU1RMf4OevW8xvdApKQq4YblgulUClVwpa0qDK8So5x7FcGX9TyXJjCN-4IXs7L1OERRblQSwceN6KKj13hIaLebyo1IaD641zwcj9uecmGrCI7Xii3djvFhEFXjvFmWuWdecLAwgr1O339GFg7vcEYj-LRZAP__rP1HSR3A8y7Zx5_aHEJv9bPBI4djVvpDWMK_AdRA6yw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Selenium+in+the+Treatment+of+Head+and+Neck+Lymphedema&rft.jtitle=Medical+principles+and+practice&rft.au=Bruns%2C+F.&rft.au=B%C3%BCntzel%2C+J.&rft.au=M%C3%BCcke%2C+R.&rft.au=Sch%C3%B6nekaes%2C+K.&rft.date=2004-01-01&rft.issn=1011-7571&rft.eissn=1423-0151&rft.volume=13&rft.issue=4&rft.spage=185&rft.epage=190&rft_id=info:doi/10.1159%2F000078313&rft.externalDBID=n%2Fa&rft.externalDocID=10_1159_000078313 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-7571&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-7571&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-7571&client=summon |